Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.

Tytuł:
Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.
Autorzy:
Sandborn WJ; Department of Medicine, Division of Gastroenterology, University of California San Diego, La Jolla, California, USA.
Lee SD; Department of Medicine, Division of Gastroenterology, University of Washington, Seattle, Washington, USA.
Tarabar D; Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia.
Louis E; Department of Gastroenterology, University Hospital CHU of Liege, Liège, Belgium.
Klopocka M; Department of Vascular Diseases and Internal Medicine, Nicolaus Copernicus University, Toruń, Collegium Medicum in Bydgoszcz, Poland.
Klaus J; Department of Medicine, Universitatsklinikum Ulm, Ulm, Germany.
Reinisch W; Department of Medicine, Division of Gastroenterology, Medical University of Vienna, Vienna, Austria.; Division of Gastroenterology, Department of Medicine, McMaster University, Hamilton, Canada.
Hébuterne X; Department of Medicine, Université de Nice Sophia Antipolis, Hôpital de l'Archet, Nice, France.
Park DI; Department of Internal Medicine, Division of Gastroenterology, Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea.
Schreiber S; Department of Medicine, University of Kiel, Kiel, Germany.
Nayak S; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Ahmad A; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Banerjee A; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Brown LS; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Cataldi F; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Gorelick KJ; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Cheng JB; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Hassan-Zahraee M; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
Clare R; Department of Gastroenterology, Pfizer, Cambridge, Massachusetts, USA.
D'Haens GR; IBD Unit, Academic Medical Center, Amsterdam, The Netherlands.
Źródło:
Gut [Gut] 2018 Oct; Vol. 67 (10), pp. 1824-1835. Date of Electronic Publication: 2017 Oct 05.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Original Publication: London, British Medical Assn.
MeSH Terms:
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/adverse effects
Crohn Disease*/diagnosis
Crohn Disease*/drug therapy
Crohn Disease*/metabolism
Adult ; Aged ; C-Reactive Protein/analysis ; Colonoscopy/methods ; Dose-Response Relationship, Drug ; Double-Blind Method ; Drug Monitoring/methods ; Female ; Gastrointestinal Agents/administration & dosage ; Gastrointestinal Agents/adverse effects ; Humans ; Male ; Middle Aged ; Patient Acuity ; Severity of Illness Index ; Treatment Outcome
References:
N Engl J Med. 2010 Apr 15;362(15):1383-95. (PMID: 20393175)
Gastroenterology. 1976 Mar;70(3):439-44. (PMID: 1248701)
N Engl J Med. 2016 Nov 17;375(20):1946-1960. (PMID: 27959607)
Gastroenterology. 2013 Jul;145(1):149-157.e2. (PMID: 23528626)
Gastrointest Endosc. 2004 Oct;60(4):505-12. (PMID: 15472670)
Gut. 2017 May;66(5):839-851. (PMID: 26893500)
Am J Gastroenterol. 2009 Feb;104(2):465-83; quiz 464, 484. (PMID: 19174807)
N Engl J Med. 2003 Jan 2;348(1):24-32. (PMID: 12510039)
N Engl J Med. 2013 Aug 22;369(8):711-21. (PMID: 23964933)
Gut. 2011 Aug;60(8):1068-75. (PMID: 21317177)
Br J Pharmacol. 2009 May;157(2):281-93. (PMID: 19366349)
Clin Gastroenterol Hepatol. 2008 Dec;6(12):1370-7. (PMID: 18829392)
Nature. 1989 Jan 12;337(6203):179-81. (PMID: 2911352)
Am J Pathol. 2010 Feb;176(2):556-62. (PMID: 20035048)
J Crohns Colitis. 2018 Jan 24;12(2):188-196. (PMID: 28961770)
Gastroenterology. 2004 May;126(5):1257-69. (PMID: 15131785)
Cytometry A. 2014 Jan;85(1):25-35. (PMID: 24124072)
Gastroenterology. 2010 Oct;139(4):1147-55. (PMID: 20637205)
Lancet. 2012 Nov 3;380(9853):1590-605. (PMID: 22914295)
Nature. 1988 Jan 7;331(6151):41-6. (PMID: 3340147)
Ann Intern Med. 2007 Jun 19;146(12):829-38. (PMID: 17470824)
N Engl J Med. 2012 May 17;366(20):1870-80. (PMID: 22591293)
Gastroenterology. 2005 Sep;129(3):807-18. (PMID: 16143120)
Gastroenterology. 2007 May;132(5):1672-83. (PMID: 17484865)
N Engl J Med. 2012 Oct 18;367(16):1519-28. (PMID: 23075178)
Clin Gastroenterol Hepatol. 2011 Aug;9(8):670-678.e3. (PMID: 21642014)
Clin Gastroenterol Hepatol. 2008 Jun;6(6):644-53. (PMID: 18550004)
Am J Pathol. 1997 Jul;151(1):97-110. (PMID: 9212736)
Contributed Indexing:
Keywords: crohn’s disease; inflammatory bowel disease; integrins; pharmacotherapy
Molecular Sequence:
ClinicalTrials.gov NCT01276509
Substance Nomenclature:
0 (Antibodies, Monoclonal, Humanized)
0 (Gastrointestinal Agents)
6LGI7RV4PB (ontamalimab)
9007-41-4 (C-Reactive Protein)
Entry Date(s):
Date Created: 20171007 Date Completed: 20180918 Latest Revision: 20230928
Update Code:
20240105
PubMed Central ID:
PMC6145284
DOI:
10.1136/gutjnl-2016-313457
PMID:
28982740
Czasopismo naukowe
Objective: This phase II, randomised, double-blind, placebo-controlled clinical trial was designed to evaluate the efficacy and safety of PF-00547659, a fully human monoclonal antibody that binds to human mucosal addressin cell adhesion molecule (MAdCAM) to selectively reduce lymphocyte homing to the intestinal tract, in patients with moderate-to-severe Crohn's disease (CD).
Design: Eligible adults were aged 18-75 years, with active moderate-to-severe CD (Crohn's Disease Activity Index (CDAI) 220-450), a history of failure or intolerance to antitumour necrosis factor and/or immunosuppressive agents, high-sensitivity C reactive protein >3.0 mg/L and ulcers on colonoscopy. Patients were randomised to PF-00547659 22.5 mg, 75 mg or 225 mg or placebo. The primary endpoint was CDAI 70-point decrease from baseline (CDAI-70) at week 8 or 12.
Results: In all, 265 patients were eligible for study entry. Although CDAI-70 response was not significantly different with placebo versus PF-00547659 treatment at weeks 8 or 12, remission rate was greater in patients with higher baseline C reactive protein (>5 mg/L vs >18.8 mg/L, respectively). Soluble MAdCAM decreased significantly from baseline to week 2 in a dose-related manner and remained low during the study in PF-00547659-treated patients. Circulating β 7 + CD4+ central memory T-lymphocytes increased at weeks 8 and 12 with PF-00547659 treatment. No safety signal was seen.
Conclusions: Clinical endpoint differences between PF-00547659 and placebo did not reach statistical significance in patients with moderate-to-severe CD. PF-00547659 was pharmacologically active, as shown by a sustained dose-related decrease in soluble MAdCAM and a dose-related increase in circulating β 7 + central memory T cells.
Trial Registration Number: NCT01276509; Results.
Competing Interests: Competing interests: WJS has received grant support, personal fees and non-financial support from Pfizer during the conduct of the study; grant support from Pfizer, Exact Sciences, Amgen, the American College of Gastroenterology and the Broad Foundation; grant support and personal fees from Prometheus Laboratories, AbbVie, Boehringer Ingelheim, Takeda, Atlantic Pharmaceuticals, Janssen, Bristol-Myers Squibb, Genentech and Nutrition Science Partners and personal fees from Kyowa Hakko Kirin, Millennium Pharmaceuticals, Celgene Cellular Therapeutics, Santarus, Salix Pharmaceuticals, Catabasis Pharmaceuticals, Vertex Pharmaceuticals, Warner Chilcott, Gilead Sciences, Cosmo Pharmaceuticals, Ferring Pharmaceuticals, Sigmoid Biotechnologies, Tillotts Pharma, Am Pharma BV, Dr August Wolff, Avaxia Biologics, Zyngenia, Ironwood Pharmaceuticals, Index Pharmaceuticals, Nestle, Lexicon Pharmaceuticals, UCB Pharma, Orexigen, Luitpold Pharmaceuticals, Baxter Healthcare, Ferring Research Institute, Amgen, Novo Nordisk, Mesoblast, Shire, Ardelyx, Actavis, Seattle Genetics, MedImmune (AstraZeneca), Actogenix NV, Lipid Therapeutics Gmbh, Eisai, Qu Biologics, Toray Industries, Teva Pharmaceuticals, Eli Lilly, Chiasma, TiGenix, Adherion Therapeutics, Immune Pharmaceuticals, Celgene, Arena Pharmaceuticals, Ambrx, Akros Pharma, Vascular Biogenics, Theradiag, Forward Pharma, Regeneron, Galapagos, Seres Health, Ritter Pharmaceuticals, Theravance, Palatin, Biogen and the University of Western Ontario (owner of Robarts Clinical Trials) outside the submitted work. In addition, WJS reports patents related to the use of topical azathioprine to treat inflammatory bowel disorders (US 5,691,343), topical formulations of azathioprine to treat inflammatory bowel disorders (US 5,905,081), colonic delivery of nicotine to treat inflammatory bowel disease (South African patent 97/1020; US 5,846,983, 5,889,028 and 6,166,044; Mexico patent 209636; Europe patents 0954337 and 893998; Hong Kong patent HK1019043; China patent ZL97192177; Czech patent 293616; Canada patent 2,246,235), the use of azathioprine to treat Crohn’s disease (US 5,733,915), azathioprine compositions for colonic administration (New Zealand patent 306062; Singapore patent 45647; Australia patent 707168; Czech patent 290428), intestinal absorption of nicotine to treat nicotine responsive conditions (Australia patent 718052; US 6,238,689), the use of topical azathioprine and thioguanine to treat colorectal adenomas (US 6,166,024), enema and enterically coated oral dosage forms of azathioprine (US 6,432,967), a pharmaceutical composition for the treatment of inflammatory bowel disease (US 7,341,741), intestinal absorption of nicotine to treat nicotine responsive conditions (Canada patent 2,260,909) and obesity treatment and device (US 7,803,195 B2). SDL has received financial support for research from UCB, Janssen, Abbvie, Genentech, Amgen, Takeda and Pfizer; and consulting fees from UCB, Janssen and Takeda. DT reported no disclosures. EL has received educational grants from MSD, Abbvie; speaker fees from Abbvie, Ferring, MSD, Chiesi, Mitsubishi Pharma, Hospira, Janssen and Takeda and has served on advisory boards for Abbvie, Ferring, MSD, Takeda, Mitsubishi Pharma, Celltrion and Prometheus. MK has received speaker fees from Abbvie, Alvogen, Ferring and Takeda and fees for travel/accommodations/meeting expenses from Ferring, Alvogen and Abbvie. JK reported no disclosures. WR has received financial support for research from Abbott Laboratories, Abbvie, Aesca, Centocor, Falk Pharma GmbH, Immundiagnsotik and MSD; has served as a consultant for Abbott Laboratories, Abbvie, Aesca, Amgen, AM Pharma, Astellas, AstraZeneca, Avaxia, Bioclinica, Biogen IDEC, Boehringer-Ingelheim, Bristol-Myers Squibb, Cellerix, Chemocentryx, Celgene, Centocor, Celltrion, Covance, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Galapagos, Genentech, Gilead, Grünenthal, ICON, Index Pharma, Inova, Janssen, Johnson & Johnson, Kyowa Hakko Kirin Pharma, Lipid Therapeutics, MedImmune, Millenium, Mitsubishi Tanabe Pharma, MSD, Nestle, Novartis, Ocera, Otsuka, PDL, Pharmacosmos, Pfizer, Procter & Gamble, Prometheus, Robarts Clinical Trial, Schering-Plough, Second Genome, Setpointmedical, Takeda, Therakos, Tigenix, UCB, Vifor, Zyngenia and 4S and as a speaker for Abbott Laboratories, Abbvie, Aesca, Aptalis, Centocor, Celltrion, Danone Austria, Elan, Falk Pharma GmbH, Ferring, Immundiagnostik, Mitsubishi Tanabe Pharma, MSD, Otsuka, PDL, Pharmacosmos, Schering-Plough, Shire, Takeda, Therakos, Vifor and Yakult. XH has served on advisory boards for Abbvie, Fresenius Kabi, Janssens and Takeda and has participated in educational activities for Abbvie, Arard, Ferring, Fresenius Kabi, Mayoly Spindler, MSD, Nestlé, Norgine, Nutricia and Takeda. DIP reported no disclosures. SS has received consulting/speaker fees from AbbVie, Biogen, BMS, Boehringer, Celltrion, Ferring, Hospira/Pfizer, Jansen, Merck, Novartis, Takeda and UCB. SN, AB, LSB and MHZ are employees of Pfizer. AA, FC,KJG, JBC and RC were employees of Pfizer during the OPERA study. GRD’H has served as a consultant for Abbvie, Ablynx, Amakem, AM Pharma, Avaxia, Biogen, Bristol Myers Squibb, Boerhinger Ingelheim, Celgene, Celltrion, Cosmo, Covidien, Ferring, Dr FALK Pharma, Engene, Ferring, Galapagos, Gilead, GlaxoSmithKline, Hospira, Johnson and Johnson, Medimetrics, Millenium/Takeda, Mitsubishi Pharma, Merck Sharp Dome, Mundipharma, Novonordisk, Pfizer, Prometheus laboratories/Nestle, Receptos, Robarts Clinical Trials, Salix, Sandoz, Setpoint, Shire, Teva, Tigenix, Tillotts, Topivert, Versant and Vifor and has received speaker fees from Abbvie, Ferring, Johnson and Johnson, Merck Sharp Dome, Mundipharma, Norgine, Pfizer, Shire, Millenium/Takeda, Tillotts and Vifor.
(© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies